Articles Tagged With: Oncology
-
Taletrectinib Capsules (Ibtrozi)
The U.S. Food and Drug Administration has approved a potent, selective, next-generation ROS Proto-Oncogene 1 (ROS1) receptor tyrosine kinase inhibitor, taletrectinib, for the treatment of ROS1-positive non-small cell lung cancer.
-
Researchers Have Unique Ethical Obligations in Early Phase Oncology Trials
Early phase oncology clinical trials demand a lot from participants but offer uncertain benefits in return.
-
Revumenib Tablets (Revuforj)
The U.S. Food and Drug Administration has approved the first menin inhibitor, revumenib, for the treatment of relapsing or refractory acute leukemia with a lysine methyltransferase 2A gene (also known as the mixed lineage leukemia gene) translocation in adults and pediatric patients.
-
Oncologic Emergencies
Oncologic emergencies cover a variety of conditions and complications that may occur in conjunction with malignancy. These include the initial presentations of new cancer diagnoses, complications of metastatic disease, and issues related to the adverse effects of treatment.
-
Ethical Guidance for Clinicians Facing Oncology Drug Shortages
Drug shortages have been a challenging problem for many years, but they have become even more prevalent in recent years as a result of supply chain challenges and regulatory changes.
-
Adverse Neurological Events from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors have transformed the natural history of many metastatic cancers and now are widely used. However, the activation of killer T-cells also has caused serious, often fatal complications from the treatment. The central nervous system is a common victim of these complications.
-
Pediatric Hematology/Oncology Trainees Want Ethics Expertise
Ethics education would not replace the option or need to obtain a formal ethics consultation. However, such education could lead to fewer cases during which specialists believe they need such assistance.
-
U.S. Funding Targets Cancer Rates in Low-Income Neighborhoods
National Cancer Institute to manage a $50 million program to address structural and institutional factors of poverty related to cancer.
-
Parents, IRBs Hold Different Views on Phase I Pediatric Oncology Trials
IRB members are more likely than the public to think the risks outweigh the potential medical benefits. Parents think about the possibility of caring for a child with severe cancer and no treatment alternatives. IRBs ensure trials are ethical and that pediatric subjects are not exposed to excessive risk.
-
Unique Challenges for IRBs Evaluating Radiation Oncology Study Protocols
There may be few if any radiation oncology investigators at some institutions, and radiation therapy involves rapidly advancing technology. In light of this, IRBs might lack the necessary expertise to review these studies.